Yubo International Biotech Q2 FY26 net loss widens 7.6% to $268,721; revenue holds at no revenue

YBGJ•2026-08-14

Quarterly results

Yubo International Biotech posted a net loss of USD 268,721 in the quarter ended June 30, 2026, widening 7.6% year over year. Operating loss narrowed 4.3% to USD 238,860, while sales were no revenue. Other expense rose to USD 29,860 from bad debt recognized during the quarter.

Six-month performance and balance sheet

For the six months ended June 30, net loss narrowed 4.8% to USD 563,747; operating loss improved 10.8% to USD 528,135. Cash and cash equivalents totaled USD 11,989 at June 30, 2026, with negative working capital of USD 2.74 million.

Sources

Yubo International Biotech Q2 FY26 net loss widens 7.6% to $268,721; revenue holds at no revenue

Sec

Yubo International Biotech Q2 FY26 net loss widens 7.6% to $268,721; revenue holds at no revenue

Quarterly results

Six-month performance and balance sheet

Related News

BlackRock tops 5% voting rights in Pernod Ricard, holds 6.06% stake

Neumora Q2 FY26 net loss narrows to $43.1 million

PowerCompute Q2 FY26 net loss widens to $4.6 million; revenue rises 9.8% year-over-year to $2.1 million

Sources

Yubo International Biotech Q2 FY26 net loss widens 7.6% to $268,721; revenue holds at no revenue

Diginex announces extraordinary shareholder meeting on Resulticks acquisition

Zoomcar Q1 FY27 contribution profit rises 45% to $1.65 million; net revenue climbs 2% to $2.35 million